Trials / Completed
CompletedNCT05670821
PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms
Post-marketing Surveillance of Spesolimab I.V. Infusion in Improvement of Generalized Pustular Psoriasis (GPP) With Acute Symptoms in Japan
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 52 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Non-interventional cohort study in patients with newly initiated Spesolimab to evaluate the incidence of adverse drug reactions and to understand generalized pustular psoriasis (GPP) disease activities in the real world setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Spesolimab | Spesolimab |
Timeline
- Start date
- 2023-04-18
- Primary completion
- 2025-10-06
- Completion
- 2025-10-06
- First posted
- 2023-01-04
- Last updated
- 2025-10-20
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT05670821. Inclusion in this directory is not an endorsement.